<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918709</url>
  </required_header>
  <id_info>
    <org_study_id>LG-VRCL001</org_study_id>
    <nct_id>NCT01918709</nct_id>
  </id_info>
  <brief_title>Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Multiple Dose, Cross-over, Phase I Trial to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective : To investigate pharmacokinetics after concomitant administration of
      valsartan and rosuvastatin compared to single administration of valsartan or rosuvastatin in
      healthy male volunteers

      Secondary objective : To investigate safety profiles after the administration of valsartan or
      rosuvastatin alone and concomitant administration of valsartan and rosuvastatin in healthy
      male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters of valsartan and rosuvastatin</measure>
    <time_frame>0h (pre-dosing on 6d, 20d, 34d) and 0h (pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 12h, 16h, 24h, 48h, and 72h (on 7d, 21d, 35d). Day 1 0h (only in period 1)</time_frame>
    <description>Cmax,ss and AUCτ,ss of valsartan and rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of valsartan and rosuvastatin</measure>
    <time_frame>0h (pre-dosing on 6d, 20d, 34d) and 0h (pre-dosing), 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 12h, 16h, 24h, 48h, and 72h (on 7d, 21d, 35d). Day 1 0h (only in period 1)</time_frame>
    <description>Tmax,ss, Cmin,ss, t1/2,β of valsartan and rosuvastatin
Cmax,ss and AUCτ,ss of N-desmethyl rosuvastatin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>-1d and 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 9d, 10d of Period 1, 2, 3 and 42±2d</time_frame>
    <description>Adverse event monitoring
Clinical laboratory test
Vital signs
Electrocardiography
Physical examination</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension, Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan 160mg is administered daily by mouth once a day for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)</intervention_name>
    <description>Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug</description>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <other_name>V= Valsartan = brand name : Diovan</other_name>
    <other_name>R= Rosuvastatin = brand name : Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)</intervention_name>
    <description>Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug</description>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <other_name>V= Valsartan = brand name : Diovan</other_name>
    <other_name>R= Rosuvastatin = brand name : Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)</intervention_name>
    <description>Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug</description>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <other_name>V= Valsartan = brand name : Diovan</other_name>
    <other_name>R= Rosuvastatin = brand name : Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)</intervention_name>
    <description>Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug</description>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <other_name>V= Valsartan = brand name : Diovan</other_name>
    <other_name>R= Rosuvastatin = brand name : Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)</intervention_name>
    <description>Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug</description>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <other_name>V= Valsartan = brand name : Diovan</other_name>
    <other_name>R= Rosuvastatin = brand name : Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)</intervention_name>
    <description>Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug</description>
    <arm_group_label>Valsartan 160mg, Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <other_name>V= Valsartan = brand name : Diovan</other_name>
    <other_name>R= Rosuvastatin = brand name : Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male of 20 to 45 years of age at screening

          2. 19 kg/m2 ≤ BMI≤ 27 kg/m2 at screening

          3. 90 mmHg ≤SBP&lt;140 mmHg and 60 mmHg ≤DBP&lt;90 mmHg at sitting position at screening

          4. At screening

               -  AST and ALT ≤ 1.5 times of upper normal limit

               -  Serum total bilirubin ≤ 1.5 times of upper normal limit

               -  CK ≤ 2 times of upper normal limit

          5. A subject who is able to understand the study, to participate whole periods of the
             study and to provide written informed consent voluntarily after being fully informed
             of the study objectives, procedures and study drug

        Exclusion Criteria:

          1. A subject who has medical history of or has clinically significant hepatic, renal,
             gastrointestinal, respiratory, musculoskeletal, endocrinological, neurologic,
             hematologic/oncologic, or cardiovascular disease

          2. A subject with severe renal insufficiency (CrCL &lt; 10mL/min by Cockcroft-Gault
             estimation)

          3. A subject with a history of gastrointestinal disease (e.g., ulcer, Crohn's disease) or
             surgery (except a simple appendectomy or repair of a hernia) that may influence the
             absorption of the study drug

          4. A subject with a history of drug allergies to valsartan, rosuvastatin, or other drugs
             (e.g., aspirin, antibiotics), or a history of clinically significant allergies

          5. A subject with a history of drug abuse or a positive urine drug screen for
             barbiturate, benzodiazepine, methamphetamine, cannabinoids, cocaine, or opiate

          6. A subject who has taken any prescribed medication or herbal compounds within 14 days
             before the first drug administration. In addition, a subject who has taken any
             over-the-counter drug or vitamin supplement within 7 days before the first drug
             administration. (However, investigators made the final decision on the eligibility for
             the trial if all other conditions were satisfied)

          7. A subject who has participated in any other clinical trial and received study drug
             within 60 days before the first drug administration

          8. A subject who has donated a unit of blood or blood components within 60 days or 30
             days, respectively, or received a transfusion before the first drug administration

          9. A subject who has taken the drug which inhibits or induces drug metabolism such as
             barbital

         10. A subject with unusual dietary habit which may influence on the administration,
             distribution, metabolism or excretion of drugs

         11. A subject who consumes caffeine excessively (&gt; 5 units/day)

         12. A subject with consumes alcohol excessively (&gt; 21 units/week, 1 unit = 10 mL of pure
             alcohol) or with a history of alcoholism

         13. A heavy smoker ( &gt;10 cigarettes/day)

         14. A subject of positive result in serology tests (HBV, HCV, HIV, or syphilis)

         15. A subject who has hereditary muscle disease or family history of hereditary muscle
             disease, or who has history of muscle disorder induced by drug

         16. The investigator determines whether or not the subject is eligible for the study
             after, for example, reviewing clinical laboratory results, ECG result, or for other
             reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Wook Ko, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

